Ease of Use
VBI Vaccines Inc is a biotechnology business based in the US. VBI Vaccines shares (VBIV.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.88 – a decrease of 2.37% over the previous week. VBI Vaccines employs 123 staff and has a trailing 12-month revenue of around $1.5 million.
Since the stock market crash in March caused by coronavirus, VBI Vaccines's share price has had significant positive movement.
Its last market close was $2.88, which is 48.26% up on its pre-crash value of $1.49 and 317.39% up on the lowest point reached during the March crash when the shares fell as low as $0.69.
If you had bought $1,000 worth of VBI Vaccines shares at the start of February 2020, those shares would have been worth $533.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,117.64.
|Latest market close||$2.88|
|52-week range||$0.69 - $6.93|
|50-day moving average||$2.6253|
|200-day moving average||$3.1279|
|Wall St. target price||$8.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.758|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-11-20)||4.73%|
|1 month (2020-10-30)||22.55%|
|3 months (2020-08-28)||-27.82%|
|6 months (2020-05-29)||32.11%|
|1 year (2019-11-29)||220.61%|
|2 years (2018-11-29)||81.13%|
|3 years (2017-11-29)||-40.12%|
|5 years (2015-11-27)||1,958.61%|
|Revenue TTM||USD$1.5 million|
|Gross profit TTM||USD$-5,683,000|
|Return on assets TTM||-14.92%|
|Return on equity TTM||-31.74%|
|Market capitalisation||USD$602.7 million|
TTM: trailing 12 months
There are currently 42.7 million VBI Vaccines shares held short by investors – that's known as VBI Vaccines's "short interest". This figure is 7.8% up from 39.6 million last month.
There are a few different ways that this level of interest in shorting VBI Vaccines shares can be evaluated.
VBI Vaccines's "short interest ratio" (SIR) is the quantity of VBI Vaccines shares currently shorted divided by the average quantity of VBI Vaccines shares traded daily (recently around 4.5 million). VBI Vaccines's SIR currently stands at 9.39. In other words for every 100,000 VBI Vaccines shares traded daily on the market, roughly 9390 shares are currently held short.
However VBI Vaccines's short interest can also be evaluated against the total number of VBI Vaccines shares, or, against the total number of tradable VBI Vaccines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VBI Vaccines's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 VBI Vaccines shares in existence, roughly 180 shares are currently held short) or 0.235% of the tradable shares (for every 100,000 tradable VBI Vaccines shares, roughly 235 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against VBI Vaccines.
Find out more about how you can short VBI Vaccines stock.
We're not expecting VBI Vaccines to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
VBI Vaccines's shares were split on a 1:40 basis on 2 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.
Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as $0.69 up to $6.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.9087. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Steps to owning and managing Conagra Brands stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Xilinx stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Lufax Holding stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Covetrus stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Codiak BioSciences stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Celanese Corporation stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Praxis Precision Medicines stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Kronos Bio stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing GoodRx stocks, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.